CytomX Therapeutics Inc Stock, NASDAQ:CTMX
151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080-1913
United States of America
Number of Employees: 146
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.